This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
by Zacks Equity Research
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
Agenus (AGEN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Agenus (AGEN) closed at $2.65 in the latest trading session, marking a -1.12% move from the prior day.
Here's Why You Should Invest in Vertex (VRTX) Stock Now
by Zacks Equity Research
Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Agenus (AGEN) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
Agenus (AGEN) closed the most recent trading day at $2.05, moving -0.49% from the previous trading session.
Here is What to Know Beyond Why Agenus Inc. (AGEN) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
by Zacks Equity Research
Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States
Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Agenus (AGEN) closed at $2.31, marking a -1.28% move from the previous day.
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
by Zacks Equity Research
Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.
AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID
by Zacks Equity Research
CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.
Is Trending Stock Agenus Inc. (AGEN) a Buy Now?
by Zacks Equity Research
Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up
by Zacks Equity Research
J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.
Key Factors Driving Merck's (MRK) Outperformance This Year
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
by Zacks Equity Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up
by Zacks Equity Research
FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.
Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
by Zacks Equity Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer
Is Most-Watched Stock Agenus Inc. (AGEN) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers
by Zacks Equity Research
Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.
AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.
Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
by Zacks Equity Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.